Trimethoprim: mechanisms of action, antimicrobial activity, bacterial resistance, pharmacokinetics, adverse reactions, and therapeutic indications.
about
Insights into the Mechanism of Action of Bactericidal LipophosphonoxinsCharacterization of in vitro metabolites of trimethoprim and diaveridine in pig liver microsomes by liquid chromatography combined with hybrid ion trap/time-of-flight mass spectrometry.History of antibiotics. From salvarsan to cephalosporins.Functional neuroprotection and efficient regulation of GDNF using destabilizing domains in a rodent model of Parkinson's disease.In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens.Pseudomonas aeruginosa syntrophy in chronically colonized airways of cystic fibrosis patients.Contemporary Management of Vesicoureteral Reflux.In vivo imaging of bioluminescent Escherichia coli in a cutaneous wound infection model for evaluation of an antibiotic therapy.Emerging drugs for complicated skin and skin-structure infections.Prevention of hemodialysis catheter-related blood stream infections using a cotrimoxazole-lock technique.A brief history of antibiotics and select advances in their synthesis.Subinhibitory Concentrations of Bacteriostatic Antibiotics Induce relA-Dependent and relA-Independent Tolerance to β-Lactams.The Transient Multidrug Resistance Phenotype of Salmonella enterica Swarming Cells Is Abolished by Sub-inhibitory Concentrations of Antimicrobial Compounds.Safety assessment of antibiotic and probiotic feed additives for Gallus gallus domesticus.Interaction networks, ecological stability, and collective antibiotic tolerance in polymicrobial infections.Photocontrol of Antibacterial Activity: Shifting from UV to Red Light Activation.A pharmacokinetic interaction study of didanosine coadministered with trimethoprim and/or sulphamethoxazole in HIV seropositive asymptomatic male patients.Destabilizing Domains Enable Long-Term and Inert Regulation of GDNF Expression in the Brain
P2860
Q28551859-663CD791-4630-4C84-9B7B-58025A8A1B3EQ34097276-F1C823EC-1FE2-4F4B-B9F5-FE7D78A3C971Q34262986-62B34BE1-CACF-49BD-8238-66EDE257508CQ34861724-FD50DDE3-42CC-438F-98EB-FB85F81E099BQ35739778-F136D350-F5DA-410B-823A-34C6CFD2DAC4Q36364034-32327576-5202-413B-BD90-704A80741729Q37200591-62AF3121-6A5D-43C9-AA17-6FC78AA02E55Q37489613-86A762A4-AA98-4347-9AC7-8B1F701BE6DBQ37765900-1D414DE1-98C9-4036-B096-0D3FB8D0782EQ39037973-AD3C8DE6-2646-4C78-8065-6F74886673A2Q39414195-D318E7ED-24C3-4284-BB36-B9109CDCB241Q40361184-8720B0F6-F3D9-482C-B354-8A2CB31B33BCQ41050631-A579E7C8-96C8-4B3F-A427-D177E3E98E9EQ42378843-4FBD735C-B126-4F70-8BAA-2421D309DCE2Q46304791-89FD63E0-FAB5-4CA5-93EE-EF9CC67CEC5CQ47128488-25775FB8-9E3E-49A1-A776-7BC5307B1133Q51582320-4E24AC6E-A624-4E6A-8671-C3D28C6F20D7Q57493992-B6940C57-4714-4C0F-BE46-9531468338A8
P2860
Trimethoprim: mechanisms of action, antimicrobial activity, bacterial resistance, pharmacokinetics, adverse reactions, and therapeutic indications.
description
1981 nî lūn-bûn
@nan
1981年の論文
@ja
1981年論文
@yue
1981年論文
@zh-hant
1981年論文
@zh-hk
1981年論文
@zh-mo
1981年論文
@zh-tw
1981年论文
@wuu
1981年论文
@zh
1981年论文
@zh-cn
name
Trimethoprim: mechanisms of ac ...... , and therapeutic indications.
@en
type
label
Trimethoprim: mechanisms of ac ...... , and therapeutic indications.
@en
prefLabel
Trimethoprim: mechanisms of ac ...... , and therapeutic indications.
@en
P2093
P2860
P1433
P1476
Trimethoprim: mechanisms of ac ...... , and therapeutic indications.
@en
P2093
P2860
P356
10.1002/J.1875-9114.1981.TB03548.X
P407
P577
1981-07-01T00:00:00Z